

SmartPA Criteria Proposal

Drug/Drug Class:	Skeletal Muscle Relaxants PDL Edit
First Implementation Date:	December 24, 2008
Proposed Date:	December 17, 2020
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Skeletal muscle relaxants are FDA approved to treat two different types of conditions: muscular pain or spasms from peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes. Both conditions affect patients' mobility and can affect independence in activities of daily living and work. Common musculoskeletal conditions include low back pain, neck pain, tension headaches, and myofascial pain syndrome. Spasticity is a major health concern in a number of disease entities such as spinal cord injury, multiple sclerosis, and stroke. Spasticity may also cause pain, loss of range of motion, contractures, sleep disorders and impair ambulation.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Baclofen Chlorzoxazone 250, 500mg Cyclobenzaprine Tabs (gen Flexeril®) Dantrolene Methocarbamol Orphenadrine ER Tizanidine Tabs 	<ul style="list-style-type: none"> Amrix® Carisoprodol Carisoprodol/ASA Carisoprodol/ASA/Codeine Chlorzoxazone 375, 750mg Cyclobenzaprine 7.5 mg Tabs (gen Fexmid®) Cyclobenzaprine ER Dantrium® Fexmid® Lorzone® Metaxalone Norgesic Forte Orphenadrine/ASA/Caffeine Orphengesic Forte Robaxin® Skelaxin® Soma® Tizanidine Caps Zanaflex®

Type of Criteria: Increased risk of ADE
 Appropriate Indications

Preferred Drug List
 Clinical Edit

Data Sources: Only Administrative Databases

Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Skeletal Muscle Relaxants
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Duration of therapy limit for agents for musculoskeletal conditions
 - 2 courses of therapy – 6 weeks maximum for each course annually
 - Agents for muscle spasticity exempt from therapy duration limitation:
 - Baclofen
 - Dantrolene
 - Metaxalone
 - Methocarbamol
 - Tizanidine
- Failure to achieve desired therapeutic outcomes with a trial on 5 or more preferred agents
 - Documented trial period for preferred agents **OR**
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List Edit)
Rule Type: PDL

Default Approval Period

1 year

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

References

1. Drug Effectiveness Review Project – Drug Class Review on “Skeletal Muscle Relaxants”. Center for Evidence-Based Policy, Oregon Health & Science University; April 2005; Evidence Scan, May 2014.
2. Evidence-Based Medicine and Fiscal Analysis: “Skeletal Muscle Relaxants– Therapeutic Class Review”, Conduent Business Services, L.L.C., Richmond, VA; November 2020.
3. Evidence-Based Medicine Analysis: “Skeletal Muscle Relaxants”, UMKC-DIC; October 2020.
4. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2019.
5. USPDI, Micromedex; 20120.
6. Drug Facts and Comparisons On-line; 2020.

DRAFT

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.